# US 2023/0056811 A1 · Mucoadhesive solid or semisolid ocular delivery systems based on preactivated thiomers

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0056811 A1
- Document ID: US20230056811A1
- Status: Published application
- Kind: A1
- Application number: 17/796,183
- Filed: 2021-02-05
- Published: 2023-02-23
- Earliest claimed: 2020-02-07
- Assignees: Bioadhesive Ophthalmics
- Applicants: Bioadhesive Ophthalmics
- Inventors: Jean GARREC
- Web page: https://patentgrep.com/patent/US20230056811A1

## CPC

- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 9/0051: {Ocular inserts or implants}
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 31/5575: having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/32: Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone}
- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61K 47/36: Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61P 27/02: Ophthalmic agents
- A61P 27/06: Antiglaucoma agents or miotics
- D01D 5/0007: {Electro-spinning (non-woven fabrics produced by electro-spinning D04H1/728)}
- D01F 1/10: Other agents for modifying properties
- D10B 2509/00: Medical; Hygiene
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- D01D: MECHANICAL METHODS OR APPARATUS IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS
- D01F: CHEMICAL FEATURES IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS; APPARATUS SPECIALLY ADAPTED FOR THE MANUFACTURE OF CARBON FILAMENTS
- D10B: INDEXING SCHEME ASSOCIATED WITH SUBLASSES OF SECTION D, RELATING TO TEXTILES

## Abstract

A mucoadhesive solid or semisolid ocular delivery systems that includes a matrix of preactivated thiomers, preferably under the form of ocular inserts or ocular films. The ocular delivery systems are useful for ocular drug delivery for the treatment of ocular diseases. The delivery systems of the invention can also be used for alleviating ocular conditions such as dry eye syndrome.

## Claims

### Claim at position 1

-12. (canceled)

### Claim 13

A mucoadhesive solid or semisolid ocular delivery system comprising a preactivated thiomer matrix, wherein the matrix comprises at least one preactivated thiomer selected from polymeric compounds bearing 2-mercaptonicotinic acid, 6-mercaptonicotinic acid, 2-mercaptonicotinamide, 2-mercaptoisonicotinamide, 6-mercaptonicotinamide, 6-mercaptoisonicotinamide, 6,6′-dithionicotinamide or 6-mercaptopyridoxine side chains covalently bonded through disulfide bonds to a thiolated polymer backbone.

### Claim 14 (depends on 13)

The mucoadhesive solid or semisolid ocular delivery system according to claim 13, which is an ocular insert or an ocular film.

### Claim 15 (depends on 13)

The mucoadhesive solid or semisolid ocular delivery system according to claim 13, wherein the polymer backbone is selected from a (crosslinked) homo- or co-polymer consisting of (meth)acrylic acid, (meth)acrylic acid esters, (meth)acrylamides, vinylpyrrolidone, vinylalcohol, vinylimidazole, vinylcaprolactam, divinyl glycol, polycarbophil, carbomer, allylamine, (trimethylated) chitosans, hyaluronic acid, pectins, alginates, (crosslinked) polyallylamines, polylysine, polyornithine, polyaminoamides, methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, and sodium carboxymethylcellulose, optionally exhibiting free thiol groups as side chains.

### Claim 16 (depends on 13)

The mucoadhesive solid or semisolid ocular delivery system according to claim 13, wherein the side chains of the polymeric compound are selected from: S-(2- or 6-mercapto(iso)nicotinamide)- or S-(6-mercaptopyridoxine)-cysteine-disulfides, S-(2- or 6-mercapto(iso)nicotinamide)- or S-(6-mercaptopyridoxine)-homocysteine-disulfides, S-(2- or 6-mercapto(iso)nicotinamide)- or S-(6-mercaptopyridoxine)-cysteamine-disulfides, S-(2- or 6-mercapto(iso)nicotinamide)- or S-(6-mercaptopyridoxine)-N-acetylcysteine-disulfides, S-(2- or 6-mercapto(iso)nicotinamide)- or S-(6-mercaptopyridoxine)-thioglycolic acid-disulfides, S-(2- or 6-mercapto(iso)nicotinamide)- or S-(6-mercaptopyridoxine) thiopropionic acid-disulfides, S-(2- or 6-mercapto(iso)nicotinamide)- or S-(6-mercaptopyridoxine)-4-thiobutanoic acid-disulfides, S-(2- or 6-mercapto(iso)nicotinamide)- or S-(6-mercaptopyridoxine)-mercaptobenzoic acid-disulfides, S-(2- or 6-mercapto(iso)nicotinamide)- or S-(6-mercaptopyridoxine)-mercaptonicotinic acid-disulfides, S-(2- or 6-mercapto(iso)nicotinamide)- or S-(6-mercaptopyridoxine)-glutathione-disulfides, S-(2- or 6-mercapto(iso)nicotinamide)- or S-(6-mercaptopyridoxine)-thioethylamidine-disulfides, S-(2- or 6-mercapto(iso)nicotinamide)- or S-(6-mercaptopyridoxine)-4-thiobutylamidine-disulfides, and S-(2- or 6-mercapto(iso)nicotinamide)- or S-(6-mercaptopyridoxine)-mercaptoaniline-disulfides; said side chains being attached to the polymer backbone via amide, amidine or ester bonds.

### Claim 17 (depends on 13)

The mucoadhesive solid or semisolid ocular delivery system according to claim 13, wherein the preactivated thiomer forming the matrix is under the form of nanofibers.

### Claim 18 (depends on 17)

The mucoadhesive solid or semisolid ocular delivery system according to claim 17, wherein nanofibers are obtained by electrospinning.

### Claim 19 (depends on 13)

The mucoadhesive solid or semisolid ocular delivery system according to claim 13, further comprising one or more pharmaceutically active substance.

### Claim 20 (depends on 19)

The mucoadhesive solid or semisolid ocular delivery system according to claim 19, wherein the active substance is a pharmaceutically active substance selected from IOP lowering agents; anti-inflammatories; anti-infectives; anti-allergic agents; and dry eye treatment agents.

### Claim 21 (depends on 20)

The mucoadhesive solid or semisolid ocular delivery system according to claim 20, wherein IOP lowering agents are selected from prostaglandin analogs, cholinomimetics, beta blockers, alpha adrenergic agonists, carbonic anhydrase inhibitors, Rho kinase inhibitors, NO donor agents and combinations thereof.

### Claim 22 (depends on 20)

The mucoadhesive solid or semisolid ocular delivery system according to claim 20, wherein anti-inflammatories are selected from corticosteroid anti-inflammatory drugs and nonsteroidal anti-inflammatory drugs.

### Claim 23 (depends on 20)

The mucoadhesive solid or semisolid ocular delivery system according to claim 20, wherein anti-infectives are selected from macrolides, aminosides, rifamycin, antiviral drugs and antifungal medication.

### Claim 24 (depends on 20)

The mucoadhesive solid or semisolid ocular delivery system according to claim 20, wherein anti-allergic agents are selected from H1-antihistamines and mast cell stabilizers.

### Claim 25 (depends on 13)

The mucoadhesive solid or semisolid ocular delivery system according to claim 13, further comprising one or more pharmaceutically acceptable excipient selected from: thickening agents, gelling agents, plasticizers, solubilization agents, stabilizing agents, permeation enhancers, diluents, binding agents, disintegrants, glidants, channeling agents and buffering agents.

### Claim 26 (depends on 25)

The mucoadhesive solid or semisolid ocular delivery system according to claim 25, wherein thickening and gelling agents are selected from high molecular weight crosslinked polyacrylic acid polymers, polyvinyl alcohol, polyvinylpyrrolidone, cellulose derivatives, polyethylene glycol, and hyaluronic acid; plasticizer is glycerol; solubilization and stabilizing agents are selected from cyclodextrins; the permeation enhancer is glutathione in its reduced form; the diluents are selected from sugar alcohols; the binding agents are selected from saccharides and their derivatives, disaccharides, polysaccharides and their derivatives, cellulose, modified cellulose, sugar alcohols and synthetic polymers; disintegrants are selected from crosslinked polymers and modified starch; glidants are selected from magnesium stearate, dibasic calcium phosphate, starch, microcrystalline cellulose and colloidal silicon dioxide; and channeling agents are selected from sodium chloride and polyethylene glycol.

### Claim 27 (depends on 13)

The mucoadhesive solid or semisolid ocular delivery system according to claim 13, comprising one or more pharmaceutically acceptable excipient selected from high molecular weight crosslinked polyacrylic acid polymers, polyvinyl alcohol, polyvinylpyrrolidone, cellulose, microcrystalline cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, carboxymethyl cellulose, polyethylene glycol, hyaluronic acid, glycerol, cyclodextrins, glutathione in its reduced form, sorbitol, xylitol, mannitol, saccharides and their derivatives, sucrose, lactose, polysaccharides and their derivatives, starches, sodium starch glycolate, magnesium stearate, dibasic calcium phosphate, colloidal silicon dioxide and sodium chloride.

### Claim 28 (depends on 13)

A method for treating and/or preventing an ocular disease or ocular condition in a patient, comprising administering to target site of the eye of the patient in need thereof a mucoadhesive solid or semisolid ocular delivery system according to claim 13.

### Claim 29 (depends on 28)

The method according to claim 28, wherein the ocular disease or ocular condition is selected from open angle glaucoma, macular edema, uveitis, dry eye disease, conjunctivitis, keratitis, blepharitis, endophthalmitis, trachoma, post-surgical and seasonal allergies.

### Claim 30

A method for the manufacturing of a mucoadhesive solid or semisolid ocular delivery system, comprising forming the mucoadhesive solid or semisolid ocular delivery system from a preactivated thiomer, wherein the preactivated thiomer is selected from polymeric compounds bearing 2-mercaptonicotinic acid, 6-mercaptonicotinic acid, 2-mercaptonicotinamide, 2-mercaptoisonicotinamide, 6-mercaptonicotinamide, 6-mercaptoisonicotinamide, 6,6′-dithionicotinamide or 6-mercaptopyridoxine side chains covalently bonded through disulfide bonds to a thiolated polymer backbone.

### Claim 31 (depends on 12)

The method according to claim 12, wherein the mucoadhesive solid or semisolid ocular delivery system is an ocular insert or an ocular film.
